Abstract
Purpose
Whole-brain radiation therapy (WBRT) is generally considered as an efficient strategy to improve blood–brain barrier (BBB) permeability by damaging BBB structure and is therefore, used as a promising pretreatment of chemotherapy. However, the impact of radiotherapy on leaky BBB is still controversial for the reason that BBB of metastatic brain tumor lesion had been breached by tumor metastasizing. Herein, we conducted a self-controlled study to evaluate the effect of WBRT on the permeability of BBB in non-small cell lung cancer (NSCLC) patients with brain metastases (BM).
Method
A prospective self-controlled research was performed. Radiation-naive NSCLC patients with BM were enrolled and treated with gefitinib for 2 weeks, and then concurrently combined with WBRT for 2 weeks. Plasma and cerebrospinal fluid (CSF) before and after WBRT were collected on day 15 and 29 after the initiation of gefitinib treatment. The concentrations of gefitinib in these samples were measured by HPLC.
Results
Three patients were enrolled and evaluated. The concentrations of gefitinib in plasma and CSF pre-WBRT were comparable to those of post-WBRT. Consequently, no significant change was noted in the CSF-to-plasma ratios of gefitinib before and after WBRT (2.79 ± 1.47 vs. 2.35 ± 1.74 %, p = 0.123).
Conclusions
The WBRT may not affect the BBB permeability by determining the concentration of gefitinib in NSCLC patients with BM.
References
Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’Yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, Sadetzki S, Schlehofer B, Tihan T, Wiemels JL, Wrensch M, Buffler PA, Brain Tumor Epidemiol C (2008) Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer Am Cancer Soc 113(7):1953–1968. doi:10.1002/cncr.23741
Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126
Fortin D (2004) The blood-brain barrier should not be underestimated in neuro-oncology. Rev Neurol 160(5):523–532. doi:10.1016/s0035-3787(04)70981-9
Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K, Iizasa T (2013) Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82(2):282–287. doi:10.1016/j.lungcan.2013.08.016
Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. New Engl J Med 364(10):947–955. doi:10.1056/NEJMct0807960
Ma SL, Xu YP, Deng QH, Yu XM (2009) Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer 65(2):198–203. doi:10.1016/j.lungcan.2008.10.028
Zhao J, Chen M, Zhong W, Zhang L, Li L, Xiao Y, Nie L, Hu P, Wang M (2013) Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer 14(2):188–193. doi:10.1016/j.cllc.2012.06.004
Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70(3):399–405. doi:10.1007/s00280-012-1929-4
Qin DX, Ou GF, Mo H, Song YW, Kang GL, Hu YH, Gu XZ (2001) Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol 51(4):959–962
Sandor N, Walter FR, Bocsik A, Santha P, Schilling-Toth B, Lener V, Varga Z, Kahan Z, Deli MA, Safrany G, Hegyesi H (2014) Low dose cranial irradiation-induced cerebrovascular damage is reversible in mice. PloS One 9(11):e112397
van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY (2002) Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 9(4):683–688
Khatri A, Gaber MW, Brundage RC, Naimark MD, Hanna SK, Stewart CF, Kirstein MN (2011) Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemother Pharmacol 68(3):721–731
Qin D, Ma J, Xiao J, Tang Z (1997) Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol 20(3):263–265
Qin DX, Zheng R, Tang J, Li JX, Hu YH (1990) Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys 19(6):1507–1510
Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG, Approaches New, New Approaches to Brain Tumor Therapy C (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91(1):51–58. doi:10.1007/s11060-008-9678-2
Fazakas C, Wilhelm I, Nagyoszi P, Farkas AE, Hasko J, Molnar J, Bauer H, Bauer HC, Ayaydin F, Dung NT, Siklos L, Krizbai IA (2011) Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS ONE 6(6):e20758. doi:10.1371/journal.pone.0020758
Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306–2312. doi:10.1200/jco.2006.10.0677
Fang L, Song Y, Weng X, Li F, Xu Y, Lin N (2015) Highly sensitive HPLC-DAD method for the assay of gefitinib in patient plasma and cerebrospinal fluid: application to a blood-brain barrier penetration study. Biomedical chromatogr. doi:10.1002/bmc.3520
Azad TD, Pan J, Connolly ID, Remington A, Wilson CM, Grant GA (2015) Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurg Focus 38(3):E9. doi:10.3171/2014.12.FOCUS14758
Sandor N, Walter FR, Bocsik A, Santha P, Schilling-Toth B, Lener V, Varga Z, Kahan Z, Deli MA, Safrany G, Hegyesi H (2014) Low dose cranial irradiation-induced cerebrovascular damage is reversible in mice. PLoS ONE 9(11):e112397. doi:10.1371/journal.pone.0112397
Li YQ, Chen P, Jain V, Reilly RM, Wong CS (2004) Early radiation-induced endothelial cell loss and blood-spinal cord barrier breakdown in the rat spinal cord. Radiat Res 161(2):143–152
Fauquette W, Amourette C, Dehouck M-P, Diserbo M (2012) Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res 1433:114–126
Li YQ, Chen P, Haimovitz-Friedman A, Reilly RM, Wong CS (2003) Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Res 63(18):5950–5956
Wu L, Li X, Janagam DR, Lowe TL (2014) Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors. Pharm Res 31(3):531–540. doi:10.1007/s11095-013-1196-z
Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H (2014) Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 4:126. doi:10.3389/fonc.2014.00126
Fortin D (2012) The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets 12(3):247–259
Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L, Henthorn LR (1997) ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. In: Proceedings of the American association for cancer research annual meeting, vol 38, p 633
Rieger L, Rieger J, Winter S, Streffer J, Esser P, Dichgans J, Meyermann R, Weller M (2000) Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Acta Neuropathol 99(5):555–562
Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE (2008) Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 14(4):1266–1273. doi:10.1158/1078-0432.CCR-07-1606
Baumann M, Krause M (2004) Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72(3):257–266. doi:10.1016/j.radonc.2004.07.007
Acknowledgments
This study was supported by the Zhejiang Cancer Hospital Program for the Cultivation of 1022 Talents (Luo Fang), Zhejiang Provincial Program for the Cultivation of High-level Innovative Heath Talents (Nengming Lin), and Zhejiang Provincial Natural Science Foundation (LY15H310003; Nengming Lin).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical standard
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Fang, L., Sun, X., Song, Y. et al. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study. Cancer Chemother Pharmacol 76, 873–877 (2015). https://doi.org/10.1007/s00280-015-2847-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2847-z